Further, if ANP was to receive a Rare Pediatric Disease Priority Review Voucher, then that is worth multiples of the current market cap alone. As an example, Neuren (NEU) noted on page 8 of its recent Corporate Presentation that the average sale price of this voucher in 2019 was USD $100 million...DYOR.
Ann: Trading Halt, page-17
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.1¢ |
Change
0.002(2.53%) |
Mkt cap ! $85.85M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.1¢ | 7.9¢ | $110.7K | 1.388M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 552412 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 217684 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |